A citation-based method for searching scientific literature

Simon Eschweiler, James Clarke, Ciro Ramírez-Suástegui, Bharat Panwar, Ariel Madrigal, Serena J Chee, Ioannis Karydis, Edwin Woo, Aiman Alzetani, Somaia Elsheikh, C J Hanley, G J Thomas, Peter S Friedmann, Tilman Sanchez-Elsner, Ferhat Ay, Christian H Ottensmeier, Pandurangan Vijayanand. Nat Immunol 2021
Times Cited: 5







List of co-cited articles
10 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, Rachel Rosenthal, Sofie Ramskov, Rikke Lyngaa, Sunil Kumar Saini, Mariam Jamal-Hanjani, Gareth A Wilson, Nicolai J Birkbak, Crispin T Hiley,[...]. Science 2016
40

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity.
David Wang, Jason Quiros, Kelly Mahuron, Chien-Chun Pai, Valeria Ranzani, Arabella Young, Stephanie Silveria, Tory Harwin, Arbi Abnousian, Massimiliano Pagani,[...]. Cell Rep 2018
105
40

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Adam D Cohen, David A Schaer, Cailian Liu, Yanyun Li, Daniel Hirschhorn-Cymmerman, Soo Chong Kim, Adi Diab, Gabrielle Rizzuto, Fei Duan, Miguel A Perales,[...]. PLoS One 2010
171
40

An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion.
Aikaterini Hatzioannou, Aggelos Banos, Theodore Sakelaropoulos, Constantinos Fedonidis, Maria-Sophia Vidali, Maren Köhne, Kristian Händler, Louis Boon, Ana Henriques, Vasiliki Koliaraki,[...]. Nat Immunol 2020
36
40

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Isabelle Solomon, Maria Amann, Anne Goubier, Frederick Arce Vargas, Dimitrios Zervas, Chen Qing, Jake Y Henry, Ehsan Ghorani, Ayse U Akarca, Teresa Marafioti,[...]. Nat Cancer 2020
19
40

Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus.
Yongqiang Feng, Aaron Arvey, Takatoshi Chinen, Joris van der Veeken, Georg Gasteiger, Alexander Y Rudensky. Cell 2014
232
40

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.
Mauro Di Pilato, Edward Y Kim, Bruno L Cadilha, Jasper N Prüßmann, Mazen N Nasrallah, Davide Seruggia, Shariq M Usmani, Sandra Misale, Valentina Zappulli, Esteban Carrizosa,[...]. Nature 2019
78
40

Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity.
Abigail E Overacre-Delgoffe, Maria Chikina, Rebekah E Dadey, Hiroshi Yano, Erin A Brunazzi, Gulidanna Shayan, William Horne, Jessica M Moskovitz, Jay K Kolls, Cindy Sander,[...]. Cell 2017
226
40

Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity.
Hidetoshi Nakagawa, Jessica M Sido, Edwin E Reyes, Valerie Kiers, Harvey Cantor, Hye-Jung Kim. Proc Natl Acad Sci U S A 2016
84
40

PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance.
Catherine L Tan, Juhi R Kuchroo, Peter T Sage, Dan Liang, Loise M Francisco, Jessica Buck, Youg Raj Thaker, Qianxia Zhang, Shannon L McArdel, Vikram R Juneja,[...]. J Exp Med 2021
33
40

Cold Tumors: A Therapeutic Challenge for Immunotherapy.
Paola Bonaventura, Tala Shekarian, Vincent Alcazer, Jenny Valladeau-Guilemond, Sandrine Valsesia-Wittmann, Sebastian Amigorena, Christophe Caux, Stéphane Depil. Front Immunol 2019
259
20

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Justin F Gainor, Alice T Shaw, Lecia V Sequist, Xiujun Fu, Christopher G Azzoli, Zofia Piotrowska, Tiffany G Huynh, Ling Zhao, Linnea Fulton, Katherine R Schultz,[...]. Clin Cancer Res 2016
618
20


Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Samra Turajlic, Kevin Litchfield, Hang Xu, Rachel Rosenthal, Nicholas McGranahan, James L Reading, Yien Ning S Wong, Andrew Rowan, Nnennaya Kanu, Maise Al Bakir,[...]. Lancet Oncol 2017
415
20

Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj. Nat Rev Immunol 2009
20


The path to reactivation of antitumor immunity and checkpoint immunotherapy.
Hye-Jung Kim, Harvey Cantor. Cancer Immunol Res 2014
20
20

Genomic correlates of response to immune checkpoint blockade.
Tanya E Keenan, Kelly P Burke, Eliezer M Van Allen. Nat Med 2019
167
20

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
322
20

The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou. Front Oncol 2020
11
20

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban,[...]. J Thorac Oncol 2018
70
20

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, Lu Sun, Chunying Song, Blanca Homet Moreno, Siwen Hu-Lieskovan, Beata Berent-Maoz, Jia Pang, Bartosz Chmielowski, Grace Cherry,[...]. Cell 2016
20

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.
Patrick H Lizotte, Elena V Ivanova, Mark M Awad, Robert E Jones, Lauren Keogh, Hongye Liu, Ruben Dries, Christina Almonte, Grit S Herter-Sprie, Abigail Santos,[...]. JCI Insight 2016
79
20


Mechanisms of resistance to immune checkpoint inhibitors.
Russell W Jenkins, David A Barbie, Keith T Flaherty. Br J Cancer 2018
467
20

STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort.
Simon Papillon-Cavanagh, Parul Doshi, Radu Dobrin, Joseph Szustakowski, Alice M Walsh. ESMO Open 2020
48
20


Determinants and clinical implications of chromosomal instability in cancer.
Laurent Sansregret, Bart Vanhaesebroeck, Charles Swanton. Nat Rev Clin Oncol 2018
123
20

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
Corinne Faivre-Finn, David Vicente, Takayasu Kurata, David Planchard, Luis Paz-Ares, Johan F Vansteenkiste, David R Spigel, Marina C Garassino, Martin Reck, Suresh Senan,[...]. J Thorac Oncol 2021
54
20

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
M D Hellmann, T-W Kim, C B Lee, B-C Goh, W H Miller, D-Y Oh, R Jamal, C-E Chee, L Q M Chow, J F Gainor,[...]. Ann Oncol 2019
36
20

Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).
David E Gerber, James J Urbanic, Corey Langer, Chen Hu, I-Fen Chang, Bo Lu, Benjamin Movsas, Robert Jeraj, Walter J Curran, Jeffrey D Bradley. Clin Lung Cancer 2017
34
20

Cancer-related inflammation.
Juliana Candido, Thorsten Hagemann. J Clin Immunol 2013
378
20

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.
Michael Offin, Robin Guo, Stephanie L Wu, Joshua Sabari, Josiah D Land, Ai Ni, Joseph Montecalvo, Darragh F Halpenny, Larry W Buie, Terry Pak,[...]. JCO Precis Oncol 2019
48
20

Acquired and intrinsic resistance in cancer immunotherapy.
Sander Kelderman, Ton N M Schumacher, John B A G Haanen. Mol Oncol 2014
109
20

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
278
20

Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Makoto Sumitomo, Kiyoshi Takahara, Kenji Zennami, Tomomi Nagakawa, Yasuhiro Maeda, Kazuya Shiogama, Yasuko Yamamoto, Yoshinari Muto, Takuhisa Nukaya, Masashi Takenaka,[...]. Cancer Sci 2021
6
20

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
20

Next generation of immune checkpoint inhibitors and beyond.
Julian A Marin-Acevedo, ErinMarie O Kimbrough, Yanyan Lou. J Hematol Oncol 2021
20
20

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
552
20

Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling.
Tatiana Raskovalova, Anna Lokshin, Xiaojun Huang, Yunyun Su, Maja Mandic, Hassane M Zarour, Edwin K Jackson, Elieser Gorelik. Cancer Res 2007
87
20


The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors.
Marcin Nicoś, Paweł Krawczyk, Nicola Crosetto, Janusz Milanowski. Front Oncol 2020
5
20

Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges.
Orgilmaa Regzedmaa, Hongbing Zhang, Hongyu Liu, Jun Chen. Onco Targets Ther 2019
15
20

Tracking the Evolution of Non-Small-Cell Lung Cancer.
Mariam Jamal-Hanjani, Gareth A Wilson, Nicholas McGranahan, Nicolai J Birkbak, Thomas B K Watkins, Selvaraju Veeriah, Seema Shafi, Diana H Johnson, Richard Mitter, Rachel Rosenthal,[...]. N Engl J Med 2017
999
20

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas. Cell 2017
20

Bispecific Antibodies: From Research to Clinical Application.
Jiabing Ma, Yicheng Mo, Menglin Tang, Junjie Shen, Yanan Qi, Wenxu Zhao, Yi Huang, Yanmin Xu, Cheng Qian. Front Immunol 2021
2
50

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
115
20

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
Frank Cichocki, Ryan Bjordahl, Svetlana Gaidarova, Sajid Mahmood, Ramzey Abujarour, Hongbo Wang, Katie Tuininga, Martin Felices, Zachary B Davis, Laura Bendzick,[...]. Sci Transl Med 2020
32
20


Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei, Scott Gettinger, Everett E Vokes, Laura Q M Chow, Marco Angelo Burgio, Javier de Castro Carpeno, Adam Pluzanski, Oscar Arrieta, Osvaldo Arén Frontera, Rita Chiari,[...]. J Clin Oncol 2021
28
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.